SARS-CoV-2 Vaccines Development: Inactivated Vaccines

Sarah Issa, Dr Daniela Ovadia, Agenzia Zoe

December 09, 2020

Inactivated vaccines are produced relatively easily and are usually administered intramuscularly. They are, however, limited by the productivity of the virus in cell culture and the requirement for production facilities at a biosafety level.

Part 1: SARS-CoV-2 Vaccines Development: An Overview
Part 3: Protein-based Vaccines
Part 4: Viral Vectors
Part 5: Genetic Vaccines
Part 6: Monoclonal Antibodies

This is a snapshot of emerging vaccines during a rapidly evolving pandemic. Any and all information currently available related to COVID-19 is subject to change as more details become available. 

This article originally appeared on Univadis, part of the Medscape Professional Network. 



Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: